Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

Aims:  Aberrant histone acetylation has been associated with malignancy and histone deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials. So far, the malignancy most sensitive to HDAC inhibitors has been cutaneous T‐cell lymphoma (CTCL). The reason for this sensitivity is unclear and studies on HDAC expression and histone acetylation in CTCL are lacking. The aim of this study was to address this issue.

[1]  A. Blanca,et al.  Histone acetylation and chromatin pattern in cancer: a review. , 2008, Analytical and quantitative cytology and histology.

[2]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[3]  K. Glaser.  HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.

[4]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Peter W Hamilton,et al.  Histone acetylation and chromatin pattern in cancer. A review. , 2007, Analytical and quantitative cytology and histology.

[6]  P. Atadja,et al.  LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy. , 2006 .

[7]  T. Fojo,et al.  Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. , 2006 .

[8]  L. Verdone,et al.  Histone acetylation in gene regulation. , 2006, Briefings in functional genomics & proteomics.

[9]  K. Zatloukal,et al.  Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells , 2006, Molecular Cancer Therapeutics.

[10]  G. Jiang,et al.  The molecular mechanism of HDAC inhibitors in anticancer effects. , 2006, Cellular & molecular immunology.

[11]  Takeshi Onda,et al.  Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. , 2006, International journal of oncology.

[12]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[13]  A. Barzilai,et al.  UVB in the management of early stage mycosis fungoides , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  G. Brusa,et al.  P210 Bcr‐abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors , 2006, British journal of haematology.

[15]  S. Bates,et al.  Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide. , 2005 .

[16]  Hiroko Yamashita,et al.  Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.

[17]  M. Jung,et al.  Chromatin Modifications as Targets for New Anticancer Drugs , 2005, Archiv der Pharmazie.

[18]  S. Minucci,et al.  New method to detect histone acetylation levels by flow cytometry , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[19]  T. Kuzel,et al.  The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy , 2005, Current opinion in hematology.

[20]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[21]  S. Schreiber,et al.  Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer , 2005, Oncogene.

[22]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Grønbæk,et al.  Microarray‐based classification of diffuse large B‐cell lymphoma , 2005, European journal of haematology.

[24]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[25]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.

[26]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  T. Kuzel,et al.  Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. , 2005, Archives of dermatology.

[28]  H. M. Beier,et al.  Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis , 2005, Breast Cancer Research and Treatment.

[29]  Yoshitaka Fujii,et al.  Histone deacetylase 1 mRNA expression in lung cancer. , 2004, Lung cancer.

[30]  Hiroko Yamashita,et al.  HDAC6 Expression Is Correlated with Better Survival in Breast Cancer , 2004, Clinical Cancer Research.

[31]  V. Castronovo,et al.  Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. , 2004, European journal of histochemistry : EJH.

[32]  G. Nicolson,et al.  Expression of the metastasis‐associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas , 2004, International journal of cancer.

[33]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[34]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[35]  K. Thomsen,et al.  CD56+ lymphoma with skin involvement: clinicopathologic features and classification. , 2004, Archives of dermatology.

[36]  I. Barillot,et al.  Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). , 2004, International journal of radiation oncology, biology, physics.

[37]  D. Neal,et al.  Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.

[38]  J. Licht,et al.  ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. , 2004, Blood.

[39]  H. Kwon,et al.  Downregulation of gelsolin and retinoic acid receptor β expression in gastric cancer tissues through histone deacetylase 1 , 2004, Journal of gastroenterology and hepatology.

[40]  F. Foss.  Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches , 2003, Leukemia & lymphoma.

[41]  C. Klemke,et al.  Current Status of Cutaneous T-Cell Lymphoma: Molecular Diagnosis, Pathogenesis, Therapy and Future Directions , 2003, Oncology Research and Treatment.

[42]  Terry L. Smith,et al.  Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. , 2003, Journal of the American Academy of Dermatology.

[43]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[44]  Y. Ikeda,et al.  Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. , 2003, Oncology reports.

[45]  C. Quirk,et al.  Management of the primary cutaneous lymphomas , 2003, The Australasian journal of dermatology.

[46]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[47]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[48]  H. Kerl,et al.  Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. , 2002, Blood.

[49]  H. Kwon,et al.  Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues , 2001, Japanese journal of cancer research : Gann.

[50]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[51]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[52]  James R. Downing,et al.  ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain , 2001, Molecular and Cellular Biology.

[53]  R. Dahiya,et al.  Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.

[54]  T. Honjo,et al.  Histone Acetylation Determines the Developmentally Regulated Accessibility for T Cell Receptor γ Gene Recombination , 2001, The Journal of experimental medicine.

[55]  Eun-Joung Moon,et al.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.

[56]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[57]  T. Kuzel,et al.  Primary cutaneous B-cell lymphoma: review and current concepts. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[59]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Evans,et al.  The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. , 1998, Nucleic acids research.

[61]  M. Kashani-Sabet,et al.  Topical corticosteroids for mycosis fungoides. Experience in 79 patients. , 1998, Archives of dermatology.

[62]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[63]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[64]  A. Rademaker,et al.  Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. , 1995, Journal of the American Academy of Dermatology.

[65]  J. Lupton,et al.  Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. , 1994, Cancer letters.

[66]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[67]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[68]  L. Wood,et al.  About the Authors , 1980, European Respiratory Journal.

[69]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[70]  J. Bradner,et al.  INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS , 2005 .